Prof. Dr. Stefaan De Smedt


Ghent University
Faculty of Pharmaceutical Sciences
Laboratory of General Biochemistry and Physical Pharmacy
Campus Heymans
Ottergemsesteenweg 460
B-9000 Gent, Belgium

+32 9 264 80 76

Stefaan C. De Smedt  (°1967) studied pharmacy at Ghent University (Belgium) and received his MS degree in pharmaceutical sciences in 1990. He graduated from Ghent University in 1995. In 1995 he joined the pharmaceutical development group of Janssen Research Foundation. Since 1997 he has been a post-doctoral fellow of the Flemish Fund for Scientific Research at the Departments of Pharmacy of respectively Ghent University and the University of Utrecht (the Netherlands). In October 1999 he became Professor in Physical Pharmacy and Biopharmacy at Ghent University where he founded the Ghent Research Group on Nanomedicines. In 2007 Stefaan C. De Smedt was Guest Professor at the Catholic University of Leuven (Belgium) and from 2012 till 2014 he was appointed Guest Professor at the University of Antwerp (Belgium). Currently he is Guest Professor at the Shanghai Jiao Tong University (2016-2019), Distinguished Visiting Scientist of the Chinese Academy of Sciences at the University of Science and Technology of China (Hefei; 2017), and Specially Appointed Professor of Nanjing Foresty University (2016-2018).  He served as dean of the Faculty of Pharmaceutical Sciences at Ghent University from 2010 till 2014. Since 2014 he is a member of the Board of Directors of Ghent University. Since 2004 Dr. De Smedt serves as the European Associate Editor of the Journal of Controlled Release (JCR), being a leading journal in Pharmacology & Pharmacy; In 2015 he became Editor of JCR (for the region Europe- the Middle East & Africa). In 2015 he has been elected as member of the Belgian Royal Academy of Medicine. In 2017 he joined the board of CRIG (cancer research institute Ghent). Dr. Stefaan De Smedt filed 15 patents on carriers (and adjuvants) for drug delivery, and materials (and methods) for diagnostics.  He is a scientific founder of Memobead Technologies, a spin-off from Ghent University, whose technology was further developed by Biocartis in Lausanne (Swiss) and Mechelen (Belgium). Currently MyCartis (Ghent) commercializes the technology. Dr. De Smedt is a member of the Drug Delivery Advisory Panel of Santen (Japan) specialized in ophthalmological medicines.

Other team members

Other research groups